Hansoh Pharmaceutical's (HKG:3692) attributable profit rose 33% to 4.37 billion yuan in 2024 from 3.28 billion yuan in 2023, according to a Friday filing with the Hong Kong bourse.
Earnings per share increased to 0.73 yuan from 0.52 yuan in the previous year.
Revenue grew 21% to 12.3 billion yuan from 10.1 billion yuan a year earlier.
The company declared a final dividend of HK$0.1353 per share, payable July 25 to shareholders on record as of July 9.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。